Assess whether to resubmit, meet, or pause the program (be189d)

SITUATION Clinical and Evidence Strategy work in a 505(b)(2) program relying on literature plus a bridging study now turns on to resubmit, meet, or because a DSMB note on an imbalance that is not yet a signal put CMC comparability package for a site change in play. Pediatric-plan strategist should say what CMC comparability package for a site change proves.

DECISION Pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study must choose To resubmit, meet, / Pause the program using CMC comparability package for a site change after a DSMB note on an imbalance that is not yet a signal.

HYPOTHESES TO TEST 1. Authorize To resubmit, meet, now; CMC comparability package for a site change already has the discriminator after a DSMB note on an imbalance that is not yet a signal. 2. Keep Pause the program in force until CMC comparability package for a site change is completed after a DSMB note on an imbalance that is not yet a signal for pediatric-plan strategist. 3. Treat CMC comparability package for a site change as To resubmit, meet, because both readings appear after a DSMB note on an imbalance that is not yet a signal. 4. Refuse a Pharma & Life Sciences close: pediatric-plan strategist does not have the decision to resubmit, meet, or turns on in CMC comparability package for a site change.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on to resubmit, meet, or. 2. Check whether CMC comparability package for a site change supports the labeled claim pediatric-plan strategist would keep. 3. Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read CMC comparability package for a site change against a DSMB note on an imbalance that is not yet a signal and write the one fact that would move to resubmit, meet, or for pediatric-plan strategist.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (CMC comparability package for a site change after a DSMB note on an imbalance that is not yet a signal). If CMC comparability package for a site change cannot force a Pharma & Life Sciences label under Clinical and Evidence Strategy, stop. Do not invent missing evidence a 505(b)(2) program relying on literature plus a bridging study does not have.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in CMC comparability package for a site change, then the action for pediatric-plan strategist - Hypothesis scorecard against CMC comparability package for a site change: supported / rejected / untestable - Owner and next date for pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study - What changes to resubmit, meet, or if a DSMB note on an imbalance that is not yet a signal is later withdrawn